Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 22 Neoplasms 5 Neoplasm Metastasis 2 Urachal cancer 1 Stomach Neoplasms 1 Rectal Neoplasms 1 Pancreatic Cancer Metastatic 1 Gastro-enteropancreatic neuroendocrine tumor 1 Diabetes Mellitus, Insulin-Dependent, 12 1 Cholangiocarcinoma 1 Carcinoma, Pancreatic Ductal 1 Carcinoma, Islet Cell 1 Carcinoma, Hepatocellular 1 Borderline Resectable Pancreatic Cancer 1 Biliary Tract Neoplasms 1 Adenocarcinoma 1

Interventions

Gemcitabine 45 Cisplatin 34 Oxaliplatin 23 Capecitabine 17 Fluorouracil 13 Leucovorin 12 pembrolizumab 11 lenvatinib 11 durvalumab 10 S 1 (combination) 10 Irinotecan 10 Bevacizumab 9 apatinib 7 Nivolumab 7 tremelimumab 6 Trastuzumab 5 envafolimab 4 atezolizumab 4 Injections 4 Docetaxel 4 trametinib 3 titanium silicide 3 tislelizumab 3 irinotecan sucrosofate 3 camrelizumab 3 Radiotherapy 3 Drug Therapy 3 zanidatamab 2 toripalimab 2 surufatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Biliary Tract Neoplasms × folfirinox × Clear all

NCT03291899 2024-01-17

FBI-TRAC

King Faisal Specialist Hospital & Research Center

Phase 2 Terminated

Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡